Australian Genomics Of Chronic Allograft Dysfunction Study
Launched by WESTERN SYDNEY LOCAL HEALTH DISTRICT · Mar 10, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a research project focused on understanding kidney transplant rejection and complications. It aims to learn more about why some kidney transplants may not work as well over time. By enrolling patients who are receiving a kidney transplant, the study will follow their progress after the surgery. Researchers will look at how certain genetic factors and the body's reactions to the transplanted organ might relate to issues like chronic rejection (when the body gradually starts to reject the transplant) and the eventual loss of the kidney.
To participate in this study, individuals aged 18 to 75 who are receiving a kidney from either a living or deceased donor are eligible, as long as they can understand and agree to the study's requirements. Unfortunately, some people, including those who have had multiple organ transplants, pregnant women, children under 18, and individuals who don’t speak English, cannot take part in this research. Participants can expect to be monitored over time, helping researchers gather important information that could lead to better outcomes for kidney transplant patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Living or deceased donor kidney transplant candidate.
- • Biological sex: any
- • Ages: 18-75 years.
- • Subject must be able to understand and provide informed consent.
- • Deceased donor individuals where Research Consent has been obtained from the person consenting to organ donation at the time of organ retrieval.
- • Identifiable living donors who have received informed consent and have consented to participate in the project.
- Exclusion Criteria:
- • Presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, OR positive cross match according to site specific technique in cadaveric donor recipients.
- • Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants.
- • Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- • High risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study.
- • Non English speaking potential participants who do not understand the requirements of the study will not be included.
About Western Sydney Local Health District
Western Sydney Local Health District (WSLHD) is a leading healthcare organization dedicated to delivering high-quality medical services and advancing clinical research within the Western Sydney region. As a prominent sponsor of clinical trials, WSLHD focuses on fostering innovation and improving patient outcomes through rigorous scientific investigation. By collaborating with healthcare professionals, researchers, and community stakeholders, WSLHD aims to enhance the understanding of various health conditions and develop effective treatments, all while ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westmead, New South Wales, Australia
Westmead, New South Wales, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported